Drug Injury Watch

Side Effects News & Reports

From 2005 to the Present

All Articles by Tom Lamb

Tag: Harvoni

Health Canada: There Is No Apparent Link Between Sovaldi Or Harvoni With Liver Cancer Recurrence As Of April 2017

June 1, 2017

Drug Regulatory Agency Has Requested Additional Safety Information From Some Manufacturers Of Direct-Acting Antivirals (DAAs) (Posted by Tom Lamb at DrugInjuryWatch.com) The May 2017 edition of Health Product InfoWatch included this report, “Summary…
Continue reading…
Harvoni / Sovaldi: Spring 2017 Update On Issue Of Liver Cancer Recurrence After Using Direct-Acting Antiviral “Hep-C” Drugs

April 27, 2017

More Medical Studies Reach Different Conclusions About Whether New Hepatitis C Virus Medications Might Cause The Return Of Liver Cancer (Posted by Tom Lamb at DrugInjuryWatch.com) We continue to hear reports of patients…
Continue reading…
February 2017 Label Changes For Sovaldi, Harvoni, And Other DAA Hepatitis C Drugs Are Made So As To Add A “Black-Box” Warning

February 16, 2017

Drug Safety Regulators Flag An Increased Risk Of Hepatitis B Virus Reactivation Which Can Result In Cases Of Fulminant Hepatitis, Liver Failure, And Death (Posted by Tom Lamb at DrugInjuryWatch.com) In February…
Continue reading…
New Safety Issue: Direct-Acting Antivirals Drugs For Hepatitis C Such As Harvoni And Sovaldi Could Cause Liver Failure

January 27, 2017

January 2017 ISMP Report: FDA Database Has 524 Cases Of Liver Failure, Including 165 Deaths, And 1,058 Reports Of Severe Liver Injury (Posted by Tom Lamb at DrugInjuryWatch.com) A January 24, 2017…
Continue reading…
Is Liver Cancer Associated With Harvoni, Sovaldi, And Other Direct-Acting Antiviral Medications For Hepatitis C?

January 11, 2017

Conflicting Findings From Different Medical Studies Leave The Extent Of This Drug Safety Issue Uncertain At Present Time (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: “New Safety Issue: Direct-Acting Antivirals Drugs…
Continue reading…
Harvoni, Sovaldi, Viekira Pak, And Other Direct-Acting Antivirals Get Black-Box Warning: Risk Of Hepatitis B Virus Reactivation

October 4, 2016

October 2016 FDA Drug Safety Communication Warns About These Relatively New Drugs Which Are Increasingly Popular For Treating Chronic Hepatitis C (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: “New Safety Issue:…
Continue reading…
European Drug Regulators Consider Whether Harvoni, Sovaldi, And Other New “Hep-C” Drugs May Cause Liver Cancer Return, Hepatitis B Reactivation

April 22, 2016

These Relatively Recent Direct-Acting Antivirals Are Increasingly Popular For Treating Chronic Hepatitis C, But There Could Be Serious Side Effects In Addition To The High Costs (Posted by Tom Lamb at DrugInjuryWatch.com) …
Continue reading…
European Drug Regulators Consider Whether Harvoni, Sovaldi, And Other New “Hep-C” Drugs May Cause Liver Cancer Return, Hepatitis B Reactivation

April 22, 2016

These Relatively Recent Direct-Acting Antivirals Are Increasingly Popular For Treating Chronic Hepatitis C, But There Could Be Serious Side Effects In Addition To The High Costs (Posted by Tom Lamb at DrugInjuryWatch.com) …
Continue reading…